PCSK9 and osteoporosis: With this drug-targeted MR analysis, genetic variation within the PCSK9 gene is associated with osteoporosis risk suggesting PCSK9 inhibitors might increase this risk, whereas HMGCR inhibitors were not associated with osteoporosis.